This afternoon we watched Exelixis drop -3.2% to a price of $21.5 per share. The mid-cap Biotechnology company is now trading -16.16% below its average target price of $25.65. Analysts have set target prices ranging from $18.0 to $32.0 per share for Exelixis, and have given the stock an average rating of buy.
Exelixis's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 3.0%. The stock's short ratio is 3.96. Since 1.97% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 89.0%. In conclusion, we believe there is mixed market sentiment regarding Exelixis.
Institutions Invested in Exelixis
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-06-30 | Blackrock Inc. | 11% | 35,387,323 | $761,004,351 |
| 2023-06-30 | Vanguard Group Inc | 10% | 32,828,915 | $705,985,789 |
| 2023-06-30 | Farallon Capital Management Llc | 8% | 25,860,000 | $556,119,278 |
| 2023-06-30 | Renaissance Technologies, LLC | 5% | 14,647,589 | $314,996,389 |
| 2023-06-30 | State Street Corporation | 4% | 12,891,287 | $277,227,116 |
| 2023-06-30 | JP Morgan Chase & Company | 2% | 7,695,668 | $165,495,333 |
| 2023-06-30 | Assenagon Asset Management S.A. | 2% | 5,732,921 | $123,286,461 |
| 2023-06-30 | Meditor Group Ltd | 2% | 5,135,758 | $110,444,471 |
| 2023-06-30 | Geode Capital Management, LLC | 2% | 5,033,503 | $108,245,477 |
| 2023-06-30 | Price (T.Rowe) Associates Inc | 2% | 4,948,814 | $106,424,240 |
